Introduction

Patients treated for brain cancer at University Hospitals Coventry and Warwickshire NHS Trust are demanding a national public inquiry after an independent medical review uncovered serious failures in the trust's neuro-oncology service. The investigation, carried out by the Royal College of Physicians, examined care provided by a retired clinical oncologist and found that several people received chemotherapy for far longer than clinical guidelines recommend. Some patients were told they would die if they stopped treatment, even though that warning was not medically accurate. The trust has since apologised, but affected patients and their legal representatives say an apology is not enough.

What Happened

The review focused on the use of temozolomide, commonly known as TMZ, a chemotherapy drug used for certain brain tumours. Standard practice calls for roughly six cycles over about six months after radiotherapy. However, the investigation found that some patients under the care of the retired consultant—identified in the report as 'Dr Y'—remained on the drug for many years. One patient received more than 100 cycles across 13 years and later developed leukaemia, a known risk of excessive chemotherapy.

Another patient, a 35-year-old mother of two, was told at age 21 that she had a grade 4 glioblastoma and only six to 12 months to live. She underwent 11 years of treatment before doctors discovered she never had a brain tumour; her scans were consistent with a less serious condition called tumefactive demyelination. A father of three from Redditch described living with constant pain and depression after a decade of chemotherapy, only to learn two years ago that his original diagnosis had been wrong.

The Royal College of Physicians reviewed 20 cases directly, though it warned that many more people may have been affected. Between 2017 and 2023, 83 patients received extended TMZ treatment at the trust. Using strict criteria, the review team concluded that six patients suffered severe harm, five experienced moderate harm, and eight sustained low-level harm. Concerns about the consultant's practice were first raised by colleagues when patients were transferred to other doctors following his retirement in December 2023. He had worked at the trust from 1996 to 2024 and declined to comment to the BBC.

Why This Matters

Beyond the physical toll, the review highlighted the psychological damage caused by false cancer diagnoses and misleading advice. Patients said they were implicitly or explicitly told that stopping chemotherapy would be dangerous. In one case, a patient who questioned their treatment was allegedly told that continuing it was a legal requirement. A clinical nurse specialist who worked alongside the consultant has also retired, and the trust has made a formal referral to the Nursing and Midwifery Council.

The report also raised the possibility that deceased patients may have been harmed by non-standard chemotherapy regimes, recommending that the trust discuss a wider review with the Department of Health and Social Care and NHS England. More than 40 living patients are now pursuing legal action, and their solicitors have referred cases to the police, although no action has been taken so far.

Key Takeaways

  • An independent review by the Royal College of Physicians found serious failures in the neuro-oncology service at University Hospitals Coventry and Warwickshire NHS Trust.
  • Some brain cancer patients received temozolomide chemotherapy for years instead of the standard six-month course.
  • At least one patient was treated for 11 years for a cancer they did not have.
  • The review identified six cases of severe harm, five of moderate harm, and eight of low-level harm among the 20 cases examined.
  • More than 40 patients are taking legal action, and their representatives are calling for a statutory public inquiry.
  • The trust has apologised and launched internal and external reviews of affected patients' care.

Conclusion

University Hospitals Coventry and Warwickshire has acknowledged 'failures' and offered a sincere apology to patients who were let down. All living patients currently receiving TMZ at the trust have had their treatment re-reviewed, and an independent external clinical review will examine everyone who received more than 12 cycles under the retired consultant. Yet for the people who spent years undergoing chemotherapy they did not need, the path to accountability is just beginning. Patients say they want transparency, answers, and a formal public inquiry to ensure that nothing like this happens again.